Safety and tolerability of donepezil 23 mg in moderate to severe Alzheimer's disease |
| |
| Authors: | Martin Farlow Felix Veloso Margaret Moline Jane Yardley Elimor Brand-Schieber Francesco Bibbiani Heng Zou Timothy Hsu Andrew Satlin |
| |
| Institution: | (1) Department of Neurology, Indiana University School of Medicine, 541 Clinical Drive, CL299, Indianapolis, IN 46202, USA;(2) Centre for Clinical Cognitive Research, Pasqua Hospital, 4101 Dewdney Avenue, Regina, Saskatchewan, S4T 1A5, Canada;(3) Eisai Inc, Neuroscience Product Creation Unit, 100 Tice Blvd., Woodcliff Lake, NJ 07677, USA;(4) Eisai Ltd, Neuroscience, Mosquito Way, Hatfield, Hertfordshire, AL10 9SN, UK |
| |
| Abstract: | Background Donepezil 23 mg/d, recently approved in the United States for treatment of moderate to severe Alzheimer's disease (AD), was
developed to address the need for an additional treatment option for patients with advanced AD. This report, based on a pivotal
phase 3 study, presents a detailed analysis of the safety and tolerability of increasing donepezil to 23 mg/d compared with
continuing 10 mg/d. |
| |
| Keywords: | |
| 本文献已被 SpringerLink 等数据库收录！ |
|
